Tanvex BioPharma Inc 6541
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- TWD 68.20
- Day Range
- TWD 68.10–70.00
- 52-Week Range
- TWD 35.05–80.00
- Bid/Ask
- TWD 68.90 / TWD 69.50
- Market Cap
- TWD 11.40 Bil
- Volume/Avg
- 102,534 / 339,556
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 284.12
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 167
- Website
- https://www.tanvex.com
Comparables
Valuation
|
Metric
|
6541
|
02171
|
6617
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 7.71 | 1.56 | 4.50 |
Price/Sales | 284.12 | 347.20 | 419.23 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
6541
|
02171
|
6617
|
|---|---|---|---|
Quick Ratio | 3.16 | 9.12 | 10.19 |
Current Ratio | 3.64 | 9.47 | 10.28 |
Interest Coverage | −30.19 | −159.86 | −39.00 |
Quick Ratio
6541
02171
6617
Profitability
|
Metric
|
6541
|
02171
|
6617
|
|---|---|---|---|
Return on Assets (Normalized) | −55.62% | −29.55% | −4.63% |
Return on Equity (Normalized) | −152.67% | −39.55% | −5.29% |
Return on Invested Capital (Normalized) | −58.21% | −38.18% | −6.89% |
Return on Assets
6541
02171
6617
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Zbtpkzvxz | Bhyx | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Qdmvzdvt | Byzvzl | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Pywbyyp | Bcqzcyv | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zcwmpxv | Ghgwbtv | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Kbfzchp | Knzmb | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Rzphfsh | Jfgm | $28.1 Bil | |||
| Moderna Inc
MRNA
| Mfkqgmsx | Ctg | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Xcmklxxs | Srw | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Bycthcc | Gxcxcq | $13.4 Bil | |||
| Incyte Corp
INCY
| Nqqclzd | Bwmdyr | $12.7 Bil |
United States